key: cord-0708050-jxtmjvww
authors: Dai, Wenhao; Jochmans, Dirk; Xie, Hang; Yang, Hang; Li, Jian; Su, Haixia; Chang, Di; Wang, Jiang; Peng, Jingjing; Zhu, Lili; Nian, Yong; Hilgenfeld, Rolf; Jiang, Hualiang; Chen, Kaixian; Zhang, Leike; Xu, Yechun; Neyts, Johan; Liu, Hong
title: Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
date: 2021-04-19
journal: J Med Chem
DOI: 10.1021/acs.jmedchem.0c02258
sha: 195ab48d9e6cf90febfb6c603be1dc6ee355c848
doc_id: 708050
cord_uid: jxtmjvww

[Image: see text] A novel series of peptidomimetic aldehydes was designed and synthesized to target 3C protease (3C(pro)) of enterovirus 71 (EV71). Most of the compounds exhibited high antiviral activity, and among them, compound 18p demonstrated potent enzyme inhibitory activity and broad-spectrum antiviral activity on a panel of enteroviruses and rhinoviruses. The crystal structure of EV71 3C(pro) in complex with 18p determined at a resolution of 1.2 Å revealed that 18p covalently linked to the catalytic Cys147 with an aldehyde group. In addition, these compounds also exhibited good inhibitory activity against the 3CL(pro) and the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially compound 18p (IC(50) = 0.034 μM, EC(50) = 0.29 μM). According to our previous work, these compounds have no reasons for concern regarding acute toxicity. Compared with AG7088, compound 18p also exhibited good pharmacokinetic properties and more potent anticoronavirus activity, making it an excellent lead for further development.

Enterovirus 71 (EV71) belongs to the enterovirus genus of the picornaviridae family, and the genome of EV71 is composed of a single-stranded positive-sense RNA. To the best of our knowledge, EV71 is not only the primary pathogen of hand, foot, and mouth disease (HFMD) but also closely associated with neurological syndromes such as severe encephalitis and aseptic meningitis, and these diseases caused by the EV71 have become a worldwide health problem. Especially, young children are more susceptible to be infected by the enterovirus. 1 However, to date, there are no approved drugs to prevent or treat the associated diseases. 2 Considering the detriment of HFMD and the central neurological syndromes in children, the development of effective antiviral drugs is urgently needed.

The genome of enterovirus 71 encodes a polyprotein precursor, which is cleaved by the 3C protease (3C pro ) and 2A protease (2A pro ) into structural proteins and nonstructural proteins, of which the 3C pro is responsible for most of the cleavages. The 3C pro of enteroviruses and rhinoviruses (RV) is essential for viral replication, and it not only shared a high degree of homology at an amino acid level but also contained a Cys-His-Asp/Glu catalytic triad. In addition, the 3C pro is an exceptional cysteine protease with unique folding and catalytic mechanism, and a Gln is almost required in the P1 position of the substrates.

As far as we know, none of the known human proteases possessed a similar cleavage specificity, which makes 3C pro become a highly prospective target for developing broadspectrum drugs. 3, 4 Recent efforts in drug discovery also furnished several inhibitors against the EV71 3C pro (Figure 1 ). Those peptidomimetic compounds with a warhead in P1′ and a lactam ring in P1 could be briefly divided into reversible and irreversible inhibitors according to their binding modes. Compounds 1−6 are reversible inhibitors, among which compounds 1, 2, 4, and 5 are covalent reversible inhibitors, while 3 and 6 are noncovalent inhibitors. Those compounds exhibited good anti-EV71 activity with EC 50 values in the range of 0.009−3.7 μM, while the broad-spectrum antiviral activity and the drug-like properties were rarely evaluated. 5 Rupintrivir (AG7088) 5a was reported to have the excellent antivirus activity against EV71 with an EC 50 value of 0.009 μM and has entered clinical trials as a protease inhibitor targeting rhinovirus 3C pro , but its activity against coronaviruses is weak. Compounds 1 5b and 2 5c,d showed good anti-EV71 activity, and the selectivity of compounds 3 5e and 4 5f toward other common mammalian proteases was high, but their pharmaceutical properties were not satisfied; no more research progresses have been reported. Our compound (5 5g ) exhibited broad-spectrum antiviral activity, but its activity against EV71 was weak. As reported, the plasma stability of compounds 6 5h and 7 5i was impressive, while their pharmacokinetic properties needed to be further improved. Although many inhibitors with different warheads had been reported, there was still no effective drug on the market. With those in mind, novel broad-spectrum antiviral inhibitors with good pharmacokinetic properties and safety need to be designed.

Compound Design. AG7088 has potent anti-EV71 activity (EC 50 = 0.009 μM), so we analyzed the crystal structure of EV71 3C pro with AG7088 ( Figure 2 ) for our compound's design. 6 The results demonstrate that α,β-unsaturated ester of AG7088 forms a covalent linkage with the Cys147 residue in the S1′ subsite of the EV71 3C pro , which is the key point for maintaining the antivirus activity. The (S)-γ-lactam ring at P1 position forms hydrogen bonds with the crucial residues including Thr142 and His161 in the S1 subsite, and the substituted phenyl group at the P2 position occupies the S2 subsite well. The complex also revealed that the isopropyl in the P3 moiety is solvent-exposed, and the P4 moiety forms hydrogen bonds with Gly164, Asn145, and Ser128. 6h Unfortunately, the α,β-unsaturated ester is easily hydrolyzed, the plasma stability of the AG7088 is poor, and its half-life in rat plasma is less than 2 min; in addition, AG7088 was inactive to the SARS-CoV 3CL protease (IC 50 > 100 μM). 7 We want to overcome this shortcoming of AG7088 and obtain some novel compounds.

In our previous work, peptidomimetic α-ketoamides (compound 5) exhibited broad-spectrum antivirus activity. 5g Former reports showed that compound 1 also had good anti-EV71 activity (EC 50 = 0.096 μM). After analyzing the crystal structure of AG7088 with EV71 3C pro and comparing the structure of compound 1, compound 5, and AG7088, we found that they shared similar important key pharmacophore fragments with a warhead and (S)-γ-lactam ring. In this core structure, the warheads could be covalently linked to Cys147, and the lactam ring could interact with the crucial residues, and we envisioned AG7088 showed better antivirus activity might benefit from the additional interaction at the P3 and P4 position. When we embarked on designing the novel compounds (Figure 3 ), the key pharmacophore fragments in compounds 1, 5, and AG7088 were extracted, and then some common warheads were investigated to get compounds 19a and 19b. Subsequently, we introduced some heterocyclic moieties into the P3 position to obtain the corresponding peptidomimetic aldehydes 18b−18p. In a second approach, a valine moiety was introduced in the P3 position to keep the chain length similar to AG7088, and different heterocycles were investigated in the P4 position to get compounds 26a−26e. Chemistry. The synthetic routes and chemical structures of the compounds (19a, 19b, and 18b−18p) are shown in Scheme 1. The starting material 8 was obtained from commercial suppliers and used without further purification, and the key and N-(t-butoxycarbonyl)-L-phenylalanine 12. After the tbutoxycarbonyl group was removed from 13 by 4 M HCl in dioxane, the intermediate 14 was obtained. A subsequent coupling reaction between compound 14 and the corresponding acids 15 resulted in esters 16a−16p. The peptidomimetic aldehydes 1 and 18b−18p were approached via a two-step route, in which the ester derivatives 16a−16p were first reduced with NaBH 4 to generate the primary alcohols 17a−17p, and subsequently, 17a−17p were oxidized into aldehydes 1 and 18b−18p with Dess−Martin periodinane (DMP). Finally, compounds 19a and 19b were obtained from 1 by the Wittig reaction.

The synthetic procedure of compounds 26a−26e was shown in Scheme 2. Compound 21 was obtained via a condensation reaction between the same intermediate 14 with N-(tbutoxycarbonyl)-L-valine 20, and then, the t-butoxycarbonyl group of 21 was removed by 4 M HCl in dioxane to obtain 22. Subsequently, compound 22 was coupled with the corresponding acid 23 to afford esters 24a−24e. After completion of a reduction of the esters 24a−24e, the desired products (25a-25e) were reoxidized by DMP to obtain the final products 26a− 26e.

Structure−Activity Relationship of the Compounds. All the synthesized compounds were tested for inhibitory activity of EV71 3C pro and antiviral activity of EV71, and results are summarized in Table 1 and Table 2 .

Modification on R 1 and R 2 . Structural modifications on R 1 and R 2 were first conducted, and a number of derivatives have been designed, synthesized, and biologically evaluated. The results were summarized in Table 1 , and two compounds (compound 1 and AG7088) were used as references in this work. IC 50 values of compound 1 were inconsistent with previous reports, which might be caused by a difference in enzyme concentration. 5b These data indicated that the enzyme inhibitory activity of peptidomimetic aldehyde (compound 1, IC 50 = 4.57 ± 0.27 μM) was weaker than the compounds, in which α,β-unsaturated ester was defined as the warhead (compounds 19a and 19b), while compound 1 displayed better anti-EV71 activity (EC 50 = 0.10 ± 0.01 μM) than α,βunsaturated methyl ester 19a (EC 50 = 1.21 ± 0.14 μM) and α,β-unsaturated benzyl ester 19b (EC 50 = 3.10 ± 0.09 μM), and the antiviral results showed that a small group might be more suitable in P1′. Based on the antiviral activity, an aldehyde was selected as a new warhead for further optimization. When aldehyde on R 2 was incorporated and the R 1 moiety was replaced with heterocyclic motifs, most of the target compounds (18b−18l, 18n, and 18p) showed better 3C pro inhibitory activity (IC 50 < 4.0 μM) than compound 1 (IC 50 = 4.57 μM), indicating that the introduction of the heterocyclic ring in P3 might be able to form additional interactions with the S4 subsite to improve the inhibitory activity of 3C pro . The inhibitory activity of compound 11m was decreased, which might be due to the fact that the nitrogen atom in this compound could not form an additional interaction. As we know, the antiviral activity is a result caused by multiple factors, which was related not only to enzyme inhibitory activity but also the other properties such as permeability. So the EC 50 values deserved further discussion. The enzyme inhibitory activity of monocyclic moietysubstituted derivatives (18b, 18c) was increased, while a lower antiviral activity was observed when comparing to compound 1. Those results indicated that monocyclic moieties might not be a good choice on R 1 , and then bicyclic heterocycles were investigated. The anti-EV71 activities of compounds with heterocyclic acene moieties 18d−18h were decreased, and the Scheme 2. Synthesis Procedure of Target Compounds a a introduction of 7-bromoimidazo[1,2-a]pyridine (compound 18i) also reduced the anti-EV71 activity. Subsequently, benzoheterocycles were introduced on R 1 (18j−18p), and compounds 18j, 18k, and 18m had similar activities compared to compound 1. The introduction of methyl on quinoxaline (18l) reduced the antiviral activity; when R 1 was replaced with a substituted quinoline (18n), the anti-EV71 activity was also increased. It was noteworthy that compound 18o (EC 50 = 0.07 ± 0.01 μM) showed better anti-EV71 activity than compound 1, albeit the cytotoxicity of these compounds was slightly increased (CC 50 = 16.4 μM). The 2-indole scaffold was incorporated, and the activity of 18p against EV71 (EC 50 = 0.030 ± 0.002 μM) was increased. The discrepancy of the activities between compounds including 18h and 18j with 18p indicated that the NH moiety in the 2-indole scaffold was vital for maintaining the anti-EV71 activity.

Modification on the R 3 Position. On the other hand, as showed in Table 2 , structural modifications had been continued by introducing a valine motif at the P3 position, and most of the target compounds (26a−26e) showed good enzyme inhibitory activities (ranging from 2.43 μM to 7.49 μM), while the inhibitory activities of those compounds were weaker than AG7088 (IC 50 = 1.89 μM). We proposed the reason might be that, after replacing the carbon atom in AG7088 with a nitrogen atom, the conformation of those compounds (26a−26e) changes a lot, which made those compounds unable to occupy the binding pocket very well, and α,β-unsaturated ester showed more potent inhibitory activity against 3C pro than aldehyde. The results of antiviral activities showed that the introduction of 5methyl-1,2-oxazole and benzoheterocycles moiety on R 3 made the anti-EV71 activity of the corresponding compounds (26a− 26d) comparable to compound 1. Especially when the quinoline group was introduced into the R 3 position, compound 26d showed good activity (EC 50 = 0.043 ± 0.010 μM), while the activities of these tripeptide compounds were decreased compared with compound 18p and AG7088. In addition, compounds 26d and 18p exhibited safety cytotoxicity (CC 50 = 82.8 μM and CC 50 > 100 μM, respectively).

Crystal Structure of EV71 3C pro in Complex with 18p. To understand the binding mode of these inhibitors with the protease, the complex structure of EV71 3C pro bound with 18p was determined at a resolution of 1.2 Å. Compound 18p bound into the substrate-binding site at the surface of the protease and occupied S1, S2, and S4 subsites ( Figure 4A ). At the S1′ subsite, the aldehyde group of 18p covalently linked to the catalytic Cys147 of the protease ( Figure 4B ,C). In addition to this covalent bond, the oxygen atom of the aldehyde group established H-bonds with the side chain of catalytic His40 directly and the NH of the Gly145 main chain (part of the oxyanion hole) through a water molecule ( Figure 4C ). The (S)γ-lactam ring of 18p perfectly engaged within the S1 subsite. The oxygen atom of the (S)-γ-lactam ring formed H-bonds with the side chains of His161 and Thr142, while the nitrogen atom of the (S)-γ-lactam ring formed a H-bond with the main chain of Thr142. The benzyl ring of 18p occupied the S2 subsite by forming hydrophobic interactions with His40, Glu71, and Leu127. The indole group of 18p fitted into the S4 subsite and donated a H-bond to the main chain of Gly164. In addition, the amide bonds of 18p also participated in binding by establishing H-bonds with Ile162 and Gly164 directly and with Ser128 through a water molecule ( Figure 4C) .

A structure overlay of the EV71 3C pro -18p and the EV71 3C pro -AG7088 complexes revealed that these two compounds adopted similar binding modes ( Figure S1A ). The difference mainly lied in the interactions with the S1′ and S4 subsites. AG7088 covalently bound to the catalytic Cys147 with its α,βunsaturated ketone, while the aldehyde group of 18p was used to covalently link to the catalytic Cys147. Simultaneously, the oxygen atom of the aldehyde group participated in forming multiple H-bonds with the surrounding residues including the catalytic His40. At the S4 subsite, the indole ring of 18p flipped up and established a shorter H-bond (2.9 Å) with Gly164 compared to the H-bond (3.1 Å) between AG7088 and Gly164. In addition, a new H-bond was formed between the amide bond of 18p and Ser128, mediated by a water molecule ( Figure S1B , C).

Activity on a Panel of Enteroviruses and Rhinoviruses. Considering that the 3C proteases are conserved between different viruses, four compounds (1, 18p, 19a , and 26b) were further tested against a panel of relevant enteroviruses and rhinoviruses, and results were summarized in Table 3 . The results demonstrated that the derivatives with aldehyde warhead had potent broad-spectrum antiviral activities. Compound 1 showed better broad-spectrum antiviral activity than the α, βunsaturated ester 19a. Additionally, the dipeptide compound 18p was proved to have more efficacy than the tripeptide compound 26b. Besides, compounds 18p also exhibited excellent anti-EV68 activity (EC 50 = 0.03 ± 0.01 μM), and compounds 18p and 26b also exhibited high anti-CoxA21 activity (EC 50 = 0.43 ± 0.11 μM and EC 50 = 0.51 ± 0.01 μM, respectively), while its antiviral activities against CoxB3 and HRV were weak, which might be caused by the difference in substrate binding pockets ( Figure S2 ). According to these results, compound 18p has a lot of potential to be accessed in a broad-spectrum antiviral drug.

Antiviral Activity on SARS-CoV-2. In late December 2019, an emerged coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), causes the pandemic COVID-19 (coronavirus disease 2019). There are no specific antiviral drugs approved by the FDA except Remdesivir, so the development of more effective antiviral drugs is of great significance. 8 SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus that belongs to the β-lineage of the coronavirus. The genome is translated into two polyproteins, and then the polyproteins were cleaved by 3C-like protease (3CL pro , also named the main protease) and papain-like proteinase (PL pro ). The majority of this proteolytic processing utilizes the 3CL pro , which plays a vital role in SARS-CoV-2′s replication. Unlike enterovirus 3C pro , the active form of the SARS-CoV-2 3CL pro is a dimer, and it has a catalytic dyad containing cysteine and histidine. 9,10 As we know, the 3C pro of EV71 and 3CL pro of SARS-CoV-2 share some similarities; for example, both the catalytic sites contain cysteine and histidine, and a glutarnine (Gln) is almost always required in the P1 position of their substrates. In our previous work, we found the active sites of 3C pro and 3CL pro also are similar and usually composed of four sites: S1′, S1, S2, and S4. 5g,9d Recently, many inhibitors targeting SARS-CoV-2 3CL pro have been reported, and most of them shared similar key pharmacophore fragments (warhead and lactam ring) and exhibited good inhibitor activity against 3CL pro and replication of SARS-CoV-2 ( Figure 5 ). 9b,c,11 Among them, two peptide inhibitors developed by Pfizer (PF-007304814 is a phosphate prodrug of PF-00835231) 11b and our group (compound 29) 9d show potent antiviral activity and good safety, and both have entered phase I clinical trials. Our antienterovirus compounds show some similarity to compound Journal of Medicinal Chemistry pubs.acs.org/jmc Article 29, so some 3C pro inhibitors were selected to be further tested against 3CL pro as well as the replication of SARS-CoV-2.

The results of enzyme inhibitory activity and anti-SARS-CoV-2 activity were summarized in Table 4 . Most of the compounds showed excellent inhibitory activity of 3CL pro (IC 50 < 0.10 μM), especially when the IC 50 value of 18p was 0.034 μM. However, when the quinoline group was incorporated, the enzyme inhibitory activities were decreased (18m, 18n, and 26d). In our previous work, the 2-indole moiety could form an additional H-bond with Glu166 in the S4 subsite. 9d When 2-quinoline and the derivative (18m, 18n, and 18o) were introduced, the Hbond could not be formed, so this might be the reason for the decrease of inhibitory activity against 3CL pro . Then, the antiviral activity against SARS-CoV-2 was evaluated, of which six benzoheterocyclic dipeptide compounds exhibited excellent inhibitory activity (EC 50 < 0.5 μM), and the EC 50 values of 18o and 18p were 0.25 μM and 0.29 μM, respectively. In addition, the selection index of 18p (SI = 2786) is better than 18o (SI = 1192). The results showed the inhibitory activities of the tripeptide compounds (26a−26d) were greater than 1 μM, and the reason might be that the tripeptide compounds showed poor membrane permeability. 11 Those results indicate the compound 18p also is a good starting point for further optimization as a SARS-CoV-2 inhibitor.

Preliminary Pharmacokinetic (PK) Evaluation of Compounds 18p and 26d. To explore the further druggability of the novel peptide aldehydes, compounds 18p and 26d were evaluated for their pharmacokinetic properties in mice after intraperitoneal (20 mg/kg), subcutaneous (5 mg/kg), and intravenous (5 mg/kg) administration. As shown in Table 5 , compound 18p given intraperitoneally and subcutaneously displayed a much higher area under the curve (AUC) value than that of 26d. Compound 18p also displayed a longer half-life (T 1/2 ) of 5.85 h when administrated intravenously. Those results indicate that compound 18p has better PK properties than 26d 

In summary, a series of novel protease inhibitors with an aldehyde warhead was designed, synthesized, and biologically evaluated on EV71 by analyzing the crystal structure of EV71 3C protease with AG7088. Most of the compounds have potent inhibitory activity of 3C pro and EV71. The SAR study indicated that the introduction of aldehyde at P1′ position presented better antiviral activities than the α, β-unsaturated ester. Heteroaromatic scaffolds were introduced at the R 1 group, and most of the compounds displayed good antiviral activities, especially when R 1 is an indole moiety (18p). Compound 18p not only has high inhibitory activity of 3C pro and EV71 (3C pro : IC 50 = 2.36 μM, EV71: EC 50 = 0.030 μM), but also against EV68 (EC 50 = 0.03 μM), CoxA21 (EC 50 = 0.43 μM) and RV-B14-WT (EC 50 = 0.81 μM). It also showed moderate activity against CoxB3 (EC 50 = 4.19 μM) and RV-A02-WT (EC 50 = 1.62 μM) and low toxicity (CC 50 > 100 μM). The crystal structure of EV71 3C pro in complex with 18p was also determined at a resolution of 1.2 Å. It showed that 18p fitted into the S1′, S1, S2, and S4 sites perfectly and established multiple H-bonds with the surrounding residues including the catalytic His40. In addition, the aldehyde group of 18p covalently bound to the catalytic Cys147, which was essential for maintaining the potency of these newly designed inhibitors, and the NH in the indole group formed a hydrogen bond with the main chain of Gly164. Some compounds were further evaluated against 3CL pro and SARS-CoV-2, and the 18p also showed excellent inhibitory activity (3CL pro : IC 50 = 0.034 μM, SARS-CoV-2: EC 50 = 0.29 μM). In addition, this class of compounds also has no reasons for concern regarding acute toxicity. 9d Compared with AG7088, compound 18p exhibited good PK properties and more potent anticoronavirus activity, and it is an excellent starting point for further optimization toward a broad-spectrum antiviral drug.

General Methods. The materials and solvents were purchased from commercial sources and used without further purification. All products were characterized by their NMR and MS spectra. 1 H and 13 C NMR spectra were recorded on a 400, 500, or 600 MHz instrument. Compounds were purified by chromatography with silica gel (300−400 mesh). Analytical thin-layer chromatography (TLC) was HSGF 254 (0.15−0.2 mm thickness). Preparative thin-layer chromatography (PTLC) was HSGF 254 (0.4−0.5 mm thickness). High-resolution mass spectra (HRMS) were measured on a Micromass Ultra Q-TOF spectrometer. HPLC analysis of all final compounds was performed on Agilent-1100 HPLC with a binary pump and photodiode array detector (DAD), using an Agilent Extend-C18 column (150 mm × 4.6 mm, 5 μm). All final compounds were analyzed using MeOH/H 2 O = 70:30 (v/v) (0.8 mL/min), and all of them had an at least 95% purity.

Synthesis Procedure of Compounds. Synthetic Procedure of Compounds 9−11. The solution of lithium bis(trimethylsilyl)amide (LHMDS) (94 mL, 1 M in THF) was added dropwise to a solution of N-Boc-L-glutamic acid dimethyl ester (8) (12.0 g, 43.6 mmol) in THF (100 mL) at −78°C; then, the mixture was stirred at −78°C for 1 h. Subsequently, bromoacetonitrile (3.24 mL, 46.6 mmol) was added dropwise to the mixture under the temperature of −78°C, and the reaction was kept at −78°C for an additional 4 h. After the reactant was consumed, the reaction was quenched by NH 4 Cl (40 mL). The reaction mixture was warm up to room temperature and extracted with ethyl acetate (50 mL × 3). The organic layers were concentrated and purified by flash column chromatography (petroleum ether/ethyl acetate = 4:1) to give product 9 (7.58 g, 55%) as a colorless oil. 1 Then, in a round-bottomed flask, compound 9 (6.0 g, 19.09 mmol) was dissolved in anhydrous MeOH (100 mL) before CoCl 2 ·6H 2 O (2.72 g, 11.45 mmol) was added at 0°C. Subsequently, NaBH 4 (4.35 g, 114.78 mmol) was added porionwise, and the reaction mixture was warmed to room temperature and stirred for 12 h. After the reactant was consumed, the reaction was quenched by NH 4 Cl (30 mL). MeOH in the mixture was evaporated, and the residual mixture was extracted with ethyl acetate (50 mL × 3). The organic layers were washed by saturated NH 4 Cl solution (100 mL × 3) and brine (100 mL × 3); then, the organic phase was dried (MgSO 4 ) and concentrated. The residue was purified by flash column chromatography (petroleum ether/ethyl acetate = 2:1) to give product 10 (2.18g, 40%) as a white solid. 1 Compound 10 (1.0 g, 3.5 mmol) was dissolved in 10 mL of DCM; then, the HCl (9 mL, 4 M in dioxane) was added. The reaction mixture was stirred at 20°C for 12 h, and the mixture was concentrated in vacuo to get a white solid 11, which could be used for the following step without purification.

Synthesis Procedure of Compound 13. To a solution of Boc-L-Phe-OH 12 (1.1 g, 3.5 mmol) in DCM (40 mL) was added HATU (1.9 g, 4.9 mmol) sequentially at −20°C, and then the residue concentrated crude product 11 (0.77g 3.5 mmol) was added. After 30 min later, DIPEA (1.7 mL, 10.5 mmol) was added dropwise. Then, the reaction mixture was stirred at −20°C for 12 h. The resulting mixture was washed by saturated ammonium chloride solution (100 mL × 3), saturated NaHCO 3 solution (100 mL × 3), and brine (100 mL × 3). The organic phase layer was dried over Na 2 SO 4 and concentrated in vacuo. The resulting mixture residue was purified by column chromatography (DCM/CH 3 OH, 40:1 v/v) to afford the pure product 13 (1.26 g, 83%) as a light solid. 1 General Synthesis Procedure of Compounds 16a−16p. To a dry 100 mL flask in which 13 (1.5 g, 3.5 mmol) was dissolved with dry DCM was added 4 M HCl (9 mL, 35 mmol) slowly at 20°C, and the resulting mixture was stirred at an ambient temperature for 12 h. The solvent was removed in vacuo, and the crude product 14 was directly used in the next step without further purification. Then, trans-3phenylacrylic acid 15a (0.49 g, 1.5 mmol) was dissolved in a dry 100 mL flask with CH 2 Cl 2 , HATU (0.68g, 1.8 mmol) was added sequentially at −20°C, and then compound 14 (0.55g 1.5 mmol) was added. DIPEA (0.73 mL, 4.5 mmol) was added dropwise after 30 min. Then, the reaction mixture was stirred at −20°C for 12 h, followed by washing with a saturated ammonium chloride solution (100 mL × 3), saturated NaHCO 3 solution (100 mL × 3), and brine (100 mL × 3). The organic phase was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (CH 2 Cl 2 /CH 3 OH, 30:1 v/v) to afford the pure product 16a (0.55 g, 80%) as a light solid. 1 General Synthesis Procedure of Compounds 17a−17p. In a dry 100 mL flask was dissolved 16a (0.92 g, 2.0 mmol) in dry THF, NaBH 4 (0.6 g, 16 mmol) was added slowly at 0°C, and then, the reaction mixture was stirred at rt for 3 h. The completion of the reaction was confirmed by TLC; then the reaction was quenched and concentrated to get a crude residue. The residue was dissolved in DCM and washed with saturated ammonium chloride solution (50 mL × 3), saturated 1H) . General Synthesis Procedure of Compounds 1 and 18b−18p. To a solution of the 17a (0.87 g, 2.0 mmol) in CH 2 Cl 2 was added DMP (1.01 g, 2.4 mmol) slowly, and the reaction mixture was stirred at room temperature for 5 h. The completion of the reaction was confirmed by TLC, the reaction was quenched and concentrated, and the reaction was filtered and washed with saturated NaHCO 3 solution (50 mL × 3) and brine (50 mL × 3). The organic phase was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (DCM/CH 3 OH, 20:1 v/v) to afford the pure product 1 (0.65 g, 76%) as a light solid. 1 General Synthesis Procedure of Compounds 19a and 19b. To a solution of the 1 (0.86 g, 2.0 mmol) in CH 2 Cl 2 were added methyl-(triphenylphosphoranylidene) acetate (0.80 g, 2.4 mmol) and Et 3 N (0.56 mL, 4 mmol); then the reaction mixture was stirred at room temperature for 12 h. The completion of the reaction was confirmed by TLC; then the reaction was washed with saturated ammonium chloride solution (50 mL × 3), saturated NaHCO 3 solution (50 mL × 3), and brine (50 mL × 3). The organic phase was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (DCM/CH 3 OH, 40:1 v/v) to afford the pure product 19a (0.78 g, 78%) as a light solid.

Synthesis Procedure of Compound 21. To a solution of Boc-L-Val-OH 20 (0.76 g, 3.5 mmol) in DCM (40 mL) was added HATU (1.9 g, 4.9 mmol) sequentially at −20°C, and then the residue concentrated crude product 14 (1.28g 3.5 mmol) was added. After 30 min later, DIPEA (1.7 mL, 10.5 mmol) was added dropwise. Then, the reaction mixture was stirred at −20°C for 12 h. The resulting mixture was washed by saturated ammonium chloride solution (100 mL × 3), saturated NaHCO 3 solution (100 mL × 3), and brine (100 mL × 3). The organic phase layer was dried over Na 2 SO 4 and concentrated in vacuo. The resulting mixture residue was purified by column chromatography (DCM/CH 3 OH, 40:1 v/v) to afford the pure product 21 (1.58 g, 85%) as a light solid. 1 General Synthesis Procedure of Compounds 24a−24e. To a dry 100 mL flask in which 21 (1.86 g, 3.5 mmol) was dissolved in dry DCM was added 4 M HCl (9 mL, 35 mmol) slowly at 20°C, and the resulting mixture was stirred at an ambient temperature for 12 h. The solvent was removed in vacuo, and the crude product 22 was directly used in next step without further purification. Then compound 22 was coupled with quinaldic acid 23d to get the esters 24d (0.96 g, 80%), and the synthesis procedure is similar to 17a. 1 (d, J = 6.7 Hz, 3H) .

General Synthesis Procedure of Compounds 25a−25e. In a dry 100 mL flask was dissolved the 24d (0.88 g, 1.5 mmol) in dry THF, NaBH 4 (0.45 g, 12 mmol) was added slowly at 0°C, and then the reaction mixture was stirred at rt for 3 h. The completion of the reaction was confirmed by TLC; then the reaction was quenched and concentrated to get a crude residue. The residue was dissolved in DCM and washed with saturated ammonium chloride solution (50 mL × 3), saturated NaHCO 3 solution (50 mL × 3), and brine (50 mL × 3). The organic phase was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (DCM/CH 3 OH, 20:1 v/v) to afford the pure product 25d (0.71 g, 85%) as a light solid. 1 H NMR (400 MHz, CDCl 3 ): δ 8.60 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H) , 7.93 (t, J = 8. 1 Hz, 2H), 7.84 (d, J = 7.7 Hz, 1H), 7.65 (t, J = 7.1 Hz, 1H), 2H), 7.19 (d, J = 7.3 Hz, 2H) , 7.09 (t, J = 7. 6 Hz, 2H), 2H), 4.91 (dd, J = 14.4, 8.4 Hz, 1H), 4.45 (dd, J = 8.0, 6.7 Hz, 1H), 1H), 3.57 (ddd, J = 33.4, 11.4, 4.6 Hz, 2H), 3H), 3.17 (dd, J = 13.7, 5.7 Hz, 1H), 3.02 (dd, J = 13.7, 8.4 Hz, 1H) , 2.35 (m, 3H), 2. 1H), 1.78 (dd, J = 11.5, 9.3 Hz, 1H), 1.57 (m, 1H) , 0.97 (d, J = 6.7 Hz, 3H) , 0.92 (d, J = 6.8 Hz, 3H) .

General Synthesis Procedure of Compounds 26a−26e. To a solution of the 25d (0.56 g, 1.0 mmol) in CH 2 Cl 2 was added DMP (0.51 g, 1.2 mmol) slowly, and the reaction mixture was stirred at room temperature. The completion of the reaction was confirmed by TLC; then, the reaction was quenched and concentrated, and the reaction was filtered and washed with saturated NaHCO 3 solution (50 mL × 3) and brine (50 mL × 3). The organic phase was dried over Na 2 SO 4 and concentrated, and the residue was purified by column chromatography (DCM/CH 3 OH, 20:1 v/v) to afford the pure product 26d (0.42 g, 76%) as a light solid.

Methyl (S,E)-4-((S)-2-Cinnamamido-3-phenylpropanamido)-5-((S)-2-oxopyrrolidin-3-yl)pent-2-enoate (19a). 1 H NMR (500 MHz, acetone-d 6 ): δ 8.15 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 1H) , 7.55 (s, 1H), 7.52 (dd, J = 6.7, 2. 6 Hz, 2H), 3H), 7.31 (d, J = 7.2 Hz, 2H), 7.26 (t, J = 7.6 Hz, 3H), 1H), 7.15 (s, 1H), 6.86 (dd, J = 15.7, 5.3 Hz, 1H), 6.80 (d, J = 15.8 Hz, 1H), 5.83 (dd, J = 15.7, 1.6 Hz, 1H), 4.96 (dd, J = 14.8, 7.6 Hz, 1H) , 4. 75−4.68 (m, 1H) , 3.69 (s, 3H), 3.26 1H), 3.11 (dd, J = 13.6, 7.6 Hz, 1H) , 2.30−2.23 (m, 1H), 2.05−1.97 (m, 2H), 1.80 1H), 1.61 (td, J = 9.7, 4.9 Hz, 1H) ; 13 C NMR (125 MHz, acetoned 6 ): δ 179.4, 171.4, 166.2, 165.4, 148.5, 140.0, 137.5, 135.2, 132.0, 131.9, 131.8, 129.4, 128.8, 128.7, 128.6, 128.3, 127.7, 126.6, 121.6, 120.1, 55.2, 50.8, 48.5, 40.0, 38.0, 35.2. HRMS (ESI) Benzyl (S,E)-4-((S)-2-Cinnamamido-3-phenylpropanamido)-5-((S)-2-oxopyrrolidin-3-yl)pent-2-enoate (19b). 1 H NMR (600 MHz, CDCl 3 ): δ 7.90 (s, 1H), 7.55 (dd, J = 15.6, 2.7 Hz, 1H), 7. 2H), 9H), 7.19 (d, J = 4.1 Hz, 4H) , 7.10 (m, 1H), 6.92 (s, 1H), 6.72 (dd, J = 15.6, 5.4 Hz, 2H), 6.47 (d, J = 15.6 Hz, 1H) , 5.76 (d, J = 15.7 Hz, 1H), 5.15 (s, 2H) , 5.08 (d, J = 6.7 Hz, 1H), 4.49 (d, J = 5.3 Hz, 1H), 3.25 (m, 2H), 1H), 3.07 (dd, J = 13.5, 7.2 Hz, 1H) , 2.27 (s, 2H), 1.95 (t, J = 10.8 Hz, 1H), 1. 1H), 1H), 1.26 (d, J = 1.3 Hz, 1H ). 13 C NMR (150 MHz, CDCl 3 ): δ 179.7, 170.9, 165.6, 147.1, 141.2, 135.9, 135.5, 134.2, 129.4, 129.1, 128.4, 128.2, 128.1, 127.5, 126.6, 120.5, 119.9, 66.0, 54.1, 48.8, 48.7, 40.3, 38.7, 37.9, 34.4, 28.0 5-Methyl-N-((S)-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)isoxazole-3-carboxamide (18b). 1 H NMR (600 MHz, : δ 11.14 (d, J = 8.4 Hz, 1H), 9.41 (s, 1H), 1H), 7.78 (dd, J = 12.5, 8.8 Hz, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), NaCl, and 10% glycerol) and incubated for 10 min. The reaction was initiated by adding 40 μL of a fluorogenic substrate at a final concentration of 25 μM. The reaction solution was then incubated at 30°C for 3 h. After that, the fluorescence signal at 340 nm (excitation)/ 490 nm (emission) was measured immediately with a Bio-Tek Synergy4 plate reader.

The inhibition assay of the SARS-CoV-2 3CL pro has been described previously. 18 In brief, the recombinant SARS-CoV-2 3CL pro at a concentration of 30 nM was mixed with serial dilutions of each compound in 80 μL of assay buffer (50 mM Tris−HCl, pH 7.3, 1 mM EDTA) and incubated for 10 min. The reaction was initiated by adding 40 μL of a fluorogenic substrate (MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2) at a final concentration of 20 μM. After that, the fluorescence signal at 320 nm (excitation)/405 nm (emission) was measured immediately every 35 s for 3.5 min with a Bio-Tek Synergy4 plate reader. The velocities of reactions with compounds added at various concentrations compared to the reaction added with DMSO were calculated and used to generate inhibition profiles. For each compound, at least three independent experiments were performed for the determination of IC 50 values. The IC 50 values were expressed as the mean ± SD and determined via nonlinear regression analysis using GraphPad Prism software 8.0 (GraphPad Software, Inc., San Diego, CA, USA).

Cells. RD cells were maintained in MEM Rega-3 medium supplemented with 2% FBS, 2 mM L-glutamine, and 0.075% NaHCO 3 , all supplied by Gibco, Life Technologies. Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 .

The Vero E6 cell line was obtained from American Type Culture Collection (ATCC, no. 1586) and maintained in Dulbecco's modified Eagle medium (DMEM; Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco Invitrogen), 1% antibiotic/antimycotic (Gibco Invitrogen), at 37°C in a humidified 5% CO 2 incubator.

Viruses. Enterovirus 71 strain BrCr (EV71 BrCr), kindly provided by Prof. Dr. F. van Kuppeveld (Universiteit Utrecht, The Netherlands), was grown on RD cells. When a full cytopathic effect (CPE) was observed, the virus was harvested from the supernatants after centrifugation (10 min, 3000 rpm) and stored at −80°C. The viral titer was determined by end point titration.

A clinical isolate of SARS-CoV-2 (nCoV-2019BetaCoV/Wuhan/ WIV04/2019) was propagated in Vero E6 cells, and a viral titer was determined by TCID50. 8a All infection experiments were performed at biosafety level-3 (BSL-3).

Antiviral Assay. The anti-EV71 activity of selected compounds was tested in RD cells and seeded in a 96-well plate (2.5 × 104 cells/well). Cells were allowed to adhere overnight, after which cells were infected with EV71; a serial dilution of selected compounds was added and incubated for 4 days, i.e., until complete CPE was observed in the untreated and infected virus control conditions. CPE was subsequently quantified using an MTS-reduction assay (MTS = 3f-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt). For this, a MTS/phenazine methosulfate (PMS) stock solution (2 mg/mL MTS (Promega, Leiden, The Netherlands) and 46 μg/mL PMS (Sigma-Aldrich, Bornem, Belgium) in PBS at pH 6−6.5) was diluted 1:20 in MEM (Life Technologies, Gent, Belgium cat. no. 21090-022). The medium was aspirated from wells, and 75 μL of MTS/PMS solution was added. After 1−2 h of incubation at 37°C, the absorbance was measured at 498 nm. The % inhibition for each well is then calculated by normalization of the absorbance to the condition of untreated-infected cells (=0% inhibition) and the condition of untreated−uninfected cells (=100% inhibition). From the obtained dose−response curve, the EC 50 is calculated by curve fitting using Dotmatics software.

To assess the antiviral activity of compounds against SARS-CoV-2, preseeded Vero E6 cells (5 × 10 4 cells/well) were treated with different concentrations of the indicated compounds for 1 h and then were infected with SARS-CoV-2 at an MOI of 0.01. At 24 h pi, the cell supernatant was collected, and a viral RNA copy number in the cell supernatant was measured using real-time PCR, as described previously. 19 The antiviral activity of selected compounds against EV68, CoxA21, CoxB3, RV-A02, and RV-B14 was tested as described previously. 20 To assess the cytotoxicity of the test compounds, Vero E6 cells preseeded in a 96-well dish (2 × 10 4 cells/well) were treated with different concentrations of the indicated compounds, and 24 h later, the relative numbers of surviving cells were measured with cell counting kit-8 (GK10001, GLPBIO) according to the manufacturer's instructions.

Pharmacokinetic Profiles in CD-1 Mice. Male CD-1 mice (n = 3 per group) were treated with a solution of compounds 18p and 26d (DMSO/EtOH/PEG300/NaCl (5:5:40:50, v/v/v/v)) at doses of 20 mg/kg, 5 mg/kg, and 5 mg/kg via intraperitoneal (ip), subcutaneous (sc), and intravenous (iv), respectively. Blood samples were collected at 0. 05, 0.25, 0.75, 2, 4, 8 , and 24 h after administration. Serum samples were obtained through common procedures, and the concentrations of the compound in the supernatant were analyzed by LC-MS/MS.

All procedures relating to animal handling, care, and treatment were performed according to the guidelines approved by the Institutional Animal Care and Use Committee of the contract research organizations performing the study.

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02258.

An overlay of EV71 3C pro -18p and AG7088 complex structures; the binding pocket of 3C pro of CoXB3, RV-A02, and EV71; the anti-SARS-CoV-2 activities of compounds; the 1 H NMR and 13 C NMR spectra of target compounds; the purity of target compounds; and the crystallography data collection and refinement statistics (PDF) Molecular formula stings (CSV)

The atomic coordinates and structure factors have been deposited into the Protein Data Bank with accession code 7DNC (EV71 3C pro -18p). The authors will release the atomic coordinates and experimental data upon article publication. 

Purity: 95.0%. 5-Fluoro-N-((S)-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)-propan-2-yl)amino)-3-phenylpropan-2-yl)picolinamide (18c). 1 H NMR (600 MHz, acetone-d 6 ): δ 9

Hz, 1H), 7.98−7.94 (m, 1H), 7.37 (d, J = 7.3 Hz, 2H)

(S)-2-oxopyrrolidin-3-yl) propan-2-yl)amino)-3-phenylpropan-2-yl)benzo

3.31−3.21 (m, 3H), 2.33 (m, 2H), 2.03−1.45 (m, 3H). 13 C NMR (125 MHz

500 MHz, acetone-d 6 ): δ 9

(S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)-2,3-dihydrobenzo

)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide (18g). 1 H NMR (600 MHz, acetone-d 6 ): δ 11.14 (d, J = 8

(S)-2-oxopyrrolidin-3-yl)-propan-2-yl)amino)-3-phenylpropan-2-yl)imidazo[1,2-a]pyridine-2-carboxamide (18i). 1 H NMR (600 MHz, acetone-d 6 ): δ 9

500 MHz, acetone-d 6 ): δ 9

Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.56−7.50 (m, 1H), 7.49−7.41 (m, 2H), 7.37 (dd, J = 9

2.53− 2.27 (m, 2H), 2.04 (m, 1H), 1.86−1.62 (m, 2H). 13 C NMR (125 MHz

500 MHz, acetone-d 6 ): δ 9.47 (s, 1H), 8.69 (d, J = 8.0 Hz, 1H), 8.15 (m, 2H), 7.95 (m, 2H)

Hz, 2H), 7.25 (t, J = 7.3 Hz, 2H), 7.18 (t, J = 7.3 Hz, 1H), 6.83 (s, 1H), 5.03−4.95 (m, 1H), 3.99 (dd, J = 7.3, 4.3 Hz, 1H), 3.50 (m, 2H), 3.31−3.20 (m, 3H), 2.39−2.28 (m, 2H), 1.95−1.87 (m, 1H), 1.78− 1.68 (m, 1H), 1.62−1.51 (m, 1H). 13 C NMR

(S)-2-oxopyrrolidin-3-yl)-propan-2-yl)amino)-3-phenylpropan-2-yl)quinoxaline-2-carboxamide (18l). 1 H NMR (500 MHz, CDCl 3 ): δ 9

Hz, 1H), 8.33 (d, J = 6.2 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.80 (m, 1H), 7.75 (dd, J = 11.0, 4.0 Hz, 1H), 7.39−7.27 (m, 5H), 7.25 (d, J = 7.1 Hz, 1H), 6.56 (s, 1H)

500 MHz, CDCl 3 ): δ 9.22 (s, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.28 (d, J = 8.5 Hz, 1H), 8.22 (dd, J = 10.1, 6.0 Hz, 1H), 8.11 (m, 2H), 7.86 (d, J = 8.1 Hz, 1H), 7.77 (dd, J = 11.2, 4.1 Hz, 1H), 7.62 (m, 1H), 7.36−7.27 (m, 4H)

(S)-2-oxopyrrolidin-3-yl)-propan-2-yl) amino)-3-phenylpropan-2-yl)quinoline-2-carboxamide (18n). 1 H NMR (600 MHz

(S)-2-oxopyrrolidin-3-yl)-propan-2-yl)ami no)-3-phenylpropan-2-yl)-2H-chromene-3-carboxamide (18o). 1 H NMR (600 MHz

40 (s, 1H), 8.16 (d, J = 13

35 (s, 1H), 8.30 (d, J = 6

(S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-butan-2-yl)-1H-indole-2-carboxamide (26b). 1 H NMR (500 MHz

−7.29 (m, 1H), 7.26−7.20 (m, 3H), 7.19−7.06 (m, 4H), 7.03 (dd, J = 16.8, 9.5 Hz, 1H

(S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-butan-2-yl)benzofuran-2-carboxamide (26c). 1 H NMR (500 MHz, acetone-d 6 ): δ 9

Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.30−7.26 (m, 2H), 7.21−7.03 (m, 4H), 4.86 (m, 1H

-yl)propan-2-yl)amino)-3-phenylpropan-2-yl)amino)-butan-2-yl)quinoline-2-carboxamide (26d). 1 H NMR (500 MHz, acetone-d 6 ): δ 9

Hz, 2H), 1.30 (d, J = 5.1 Hz, 1H), 0.99 (dd, J = 19.0, 6.8 Hz, 6H). 13 C NMR (125 MHz

14 (s, 1H), 6.89 (d, J = 9

HRMS (ESI) m/z: [M − H] − calcd for C 30 H 35 N 4 O 7 , 563.2511; found, 563.2501. Purity: 95.1%. Materials and Methods. Protein Expression and Purification. The full-length gene encoding the EV71 3C pro and the SARS-CoV-2 3CL pro with an N-terminal 6 × His-SUMO2 fusion tag was cloned into the pET-15b vector. The resulting plasmids were transformed into BL21 (DE3) cells for protein expression. The expressed proteins were purified by a Ni-NTA column (GE) and transformed into the cleavage buffer (25 mM Tris, pH 7.5, 300 mM NaCl, 2 mM DTT) containing SUMO Specific Peptidase 2 (SENP2) for removing the 6 × His-SUMO2 fusion tag. The resulting protein samples were further purified by Q-Sepharose (GE Healthcare) and Superdex200 (GE Healthcare). The eluted EV71 3C pro and SARS-CoV-2 3CL pro were stored in a solution containing 25 mM Tris

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

3CL pro

TLC, thin-layer chromatography

Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People's Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study

Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind

Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of Rupintrivir, a novel human rhinovirus 3C protease inhibitor

Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Phase II, randomized, double-blind, placebo-controlled studies of Ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally

Structure-activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors

Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus

Hilgenfeld, R. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-Pyridone-containing peptidomimetics

Enterovirus 71 and Coxsackievirus A16 3C proteases: binding to Rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design

Structures of Enterovirus 71 3C proteinase (strain E2004104-TW-CDC) and its complex with rupintrivir

Liquid Chromatography-Mass spectrometry and liquid Chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. incorporation of P1 lactam moieties as L-glutamine replacements

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations

Upgrade of macromolecular crystallography beamline BL17U1 at SSRF

HKL-3000: the integration of data reduction and structure solutionfrom diffraction images to an initial model in minutes

Phaser crystallographic software

Coot: model-building tools for molecular graphics

PHENIX: building new software for automated crystallographic structure determination

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Antiviral activity of broadspectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68

Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jmedchem.0c02258Author Contributions ○ W.D., D.J., H.X., and H.Y. contributed equally to this work.

The authors declare no competing financial interest.

We are grateful to the National Natural Science Foundation of China (21632008, 21672231, 21877122, 21877118, and 81620108027) , the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12040107 and XDA12040201), and the Youth Innovation Promotion Association CAS (grants 2018367 to L.-K.Z.) for financial support ■ ABBREVIATIONS USED